olvimulogene nanivacirepvec

Phase 3

GENELUX Corp (GNLX)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Feb '27

GNLXPhase 2$114M

Olvimulogene nanivacirepvec Phase 2 Est. Readout (VIRO-25)

olvimulogene nanivacirepvec• Platinum-resistant Ovarian Cancer142

Feb 2027~Estimated

CT.gov

00%

Dec '26

GNLXPhase 3$114M

olvimulogene nanivacirepvec Phase 3 Est. Readout

olvimulogene nanivacirepvec• Platinum-resistant Ovarian Cancer186

Dec 2026~Estimated

CT.gov

00%

Competitive Landscape

1 competitor in Platinum-resistant Ovarian Cancer

CORTrelacorilant

Approved

View Full Landscape

Drug Information

Target Indication

Platinum-resistant Ovarian Cancer

Clinical Trial

NCT05281471

Last updated: 2/13/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

GNLX

GENELUX Corp

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

Platinum chemotherapy: carboplatin (preferred) or cisplatinPhase 3

Platinum-resistant Ovarian Cancer

Platinum chemotherapy: carboplatin or cisplatinPhase 2

Advanced Non-squamous Non-small-cell Lung Cancer

Olvi-VecPhase 2

Ovarian Cancer

GL-ONC1Phase 2

Peritoneal Carcinomatosis

Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLCPhase 2

Advanced Non-squamous Non-small-cell Lung Cancer

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts